Rac-Levosimendan | CAS 131741-08-7 - Request Quote
Rac-Levosimendan
| SZ CAT No: | SZ-L078003 |
| CAS No | 131741-08-7 |
| Mol.F. | C14H12N6O |
| Mol.Wt. | 280.3 |
| Inv. Status | In Stock |
Chemical Name :
Synonym :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Rac-Levosimendan is chemically N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyl dicyanide. It is also known as Simendan. Rac-Levosimendan is supplied with detailed characterization data compliant with regulatory guideline. Rac-Levosimendan can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Levosimendan.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 131741-08-7
Purchase 131741-08-7
Order 131741-08-7
Enquire 131741-08-7
price of 131741-08-7
131741-08-7 Supplier
131741-08-7 Manufacturer
131741-08-7 Exporter
buy high quality Rac-Levosimendan
Purchase Rac-Levosimendan
Rac-Levosimendan suppliers
Rac-Levosimendan manufacturers
Rac-Levosimendan price
Order Rac-Levosimendan
Enquire Rac-Levosimendan
Rac-Levosimendan cost
Rac-Levosimendan Supplier
Rac-Levosimendan Distributor
Rac-Levosimendan for Method Validation
Levosimendan Reference Standard
Rac-Levosimendan for ANDA Filing
Rac-Levosimendan for Forced Degradation Studies
Rac-Levosimendan Identification Standards
Rac-Levosimendan for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


